GlassScriptPhysician profile
Syed Zafar
NPI 1811187909
$76,460.19
in general payments reported to CMS, 2019-2025
77 companies · $8,634 in 2025
The $8,634 reported for 2025 was more than what 79% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21K · 2020: $2,878 · 2021: $2,721 · 2022: $22K · 2023: $11K · 2024: $9,317 · 2025: $8,634.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $20K · Food and Beverage: $4,687 · Honoraria: $2,400 · Travel and Lodging: $1,146 · Education: $68.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $20,427.21 |
| Food and Beverage | $4,686.62 |
| Honoraria | $2,400.00 |
| Travel and Lodging | $1,146.00 |
| Education | $68.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $8,811.73 | 2019-2025 | Imfinzi, Enhertu, Tagrisso |
| Seagen INC. | $8,714.48 | 2021-2023 | Padcev |
| Janssen Biotech, INC. | $8,297.48 | 2019-2025 | Tecvayli, Erleada, Darzalex |
| E.R. Squibb & Sons, L.L.C. | $7,065.65 | 2019-2025 | Opdivo, Opdualag |
| Glaxosmithkline, LLC. | $5,691.22 | 2020-2025 | Ojjaara, Jemperli, Zejula |
| Novartis Pharmaceuticals Corporation | $5,033.11 | 2019-2025 | Kisqali |
| Beigene USA, INC. | $4,063.23 | 2023-2024 | Brukinsa, Tevimbra |
| Taiho Oncology, INC. | $3,880.69 | 2020-2024 | |
| Verastem, INC. | $3,572.40 | 2019 | |
| Celgene Corporation | $3,300.35 | 2019-2025 | Opdualag, Reblozyl |
| Merck Sharp & Dohme LLC | $2,836.25 | 2019-2025 | Lynparza, Keytruda, Lenvima |
| Immunocore Limited | $2,485.64 | 2025 | Kimmtrak |
| Karyopharm Therapeutics INC. | $2,459.95 | 2020-2022 | |
| Morphosys, US INC. | $1,845.00 | 2022 | |
| Beigene, LTD. | $1,512.50 | 2021 |
Show all 70 companies
7 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Syed Zafar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.